arrow
P

Philipp Gödel

University of Cologne
H指数:12
被引数:2,248

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acute and long-term outcomes of CD20-targeting CAR T-cell therapy in relapsed or refractory B-NHL: MB-CART20.1 Lymphoma phase I trial

CD20靶向CAR T细胞疗法在复发或难治性B-NHL中的短期和长期疗效:MB-CART20.1淋巴瘤I期临床试验

2026-10-160
OA
Effectiveness of an on-site vaccination campaign for patients with cancer

针对癌症患者的现场疫苗接种活动的有效性

2026-09-070
OA
Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 Trial

Zamtocabtagene Autoleucel 在复发/难治性B-NHL中的应用:一项CD20/19串联CAR T细胞I期试验的5年随访研究

2026-01-130
OAAI
Early Free Light-Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA-Directed CAR-T Cells

早期游离轻链抑制作为接受BCMA靶向CAR-T细胞治疗的复发性和难治性骨髓瘤患者的预后标志物

2025-10-010
OAAI
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma

CSF1R⁺髓系-单核细胞驱动侵袭性B细胞淋巴瘤中CAR-T细胞的耐药性

2025-06-120
OAAI
An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL
2024-02-012
OAAI
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
2023-12-204
OAAI
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
2023-08-016
OAAI
Potential synergy between radiotherapy and CAR T-cells-a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy
2023-06-0120
PRE
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
2023-01-019
OAAI